NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.
Under the agreement, Enigma will develop respiratory infectious disease tests for use on its Enigma ML PCR-based platform and it will give GSK the right to market the tests and develop more based on the same platform.
The terms of the agreement call for GSK to make an up-front equity investment in Enigma, provide it with R&D-related payments and royalties based on net sales of the resulting test products, and to provide milestone payments in the future.
Further terms of the agreement were not released.
According to UK-based Enigma, the Enigma ML system can deliver a test result from a raw sample in less than one hour.
"The collaboration with Enigma provides GSK the opportunity to offer a more complete solution to the healthcare community and improve patient care through the provision of rapid, state-of-the-art diagnostic tests," Eddie Gray, GSK's President of Pharmaceuticals Europe branch, said in a statement.